摘要
目的 探讨肺表面活性物质（Ｅｘｏｓｕｒｆ） 治疗新生儿肺透明膜病（ＨＭＤ） 的疗效及其并发症。 方法 采用回顾性分析的方法对用药前、用药后３０ 分钟及用药后６ 小时血气指标，机械通气参数进行比较分析，通过肺氧合情况判断疗效，分析转归及并发症。 结果 １６ 例患儿血气指标及机械通气的参数用药前与用药后６ 小时比较差异有显著性，氧分压（ＰＯ２） 由（４１－６ ±６ ．０）ｍ ｍ Ｈｇ（１ｍ ｍ Ｈｇ＝０ ．１３ ｋＰａ） 升高至（６２－９ ±２－０） ｍ ｍ Ｈｇ，动脉压泡氧分压比值（ａ／ＡＰＯ２） 由（０－１２ ±０－０３）ｍ ｍＨｇ 升高至（０－２４ ±０－１１）ｍ ｍ Ｈｇ，ＰＯ２／ＦｉＯ２ 由（７４－６ ±１６－４）ｍ ｍＨｇ 升高至（１４７－４ ±５９－９）ｍ ｍＨｇ，ＦｉＯ２ 由０－５８±０ ．０７ 降至０－４５ ±０ ．０９ ，ＭＡＰ由（１３－０ ±１．３）ｍ ｍ Ｈｇ 降至（１１－１ ±１－６）ｍｍ Ｈｇ。２４ 小时内复查胸片１３ 例明显好转，２ 例无改变，１ 例合并肺出血。其中痊愈１２ 例（治愈率７５ ％ ），死亡２ 例，放弃２ 例。 结论 肺表面活性物质（Ｅｘｏｓｕｒｆ） 的运用可以改善肺透明膜病的转归。
Objective To explore the therapeutic effect and complications of pulmonary surfactant(Exosurf) in the treatment of hyaline membrane disease of newborn. Methods Blood gas indexes and parameter of mechanical ventilation before, 30 minute and 6 hours after the Exosurf were analyzed retrospectively. Results Before and 6 hours after the Exosurf was given, there was significant difference in blood gas indexes and parameters of mechanical ventilation of 16 newborns with HMD.PO 2 increase from 41.6±6.0 mmHg to 62.9±2.0 mmHg,a/APO 2 from 0.12±0.03 mmHg to 0.24±0.11 mmHg,PO 2/FiO 2 from 74.6±16.4 mmHg to 147.4±59.9 mmHg, FiO 2 decrease from 0.58±0.07 to 0.45±0.09, MAP from 13.9±1.3 mmHg to 11.1±1.6 mmHg, 13 newborn's chest X ray films were improved obviously in 24 hours,2 had no change,1 complicate with pulmonary hemorrhage.12 were healed, and 2 died and 2 abandoned treatment. Conclusion The pulmonary surfactant(Exosurf) can improve the prognosis of HMD, decrease the mortality, but Exosurf is synthetic pharmaceutical and the application needs further study.
出处
《中华围产医学杂志》
CAS
1999年第2期96-98,共3页
Chinese Journal of Perinatal Medicine
